Increased autophagy accelerates colchicine-induced muscle toxicity

Autophagy

Volumn 9, Issue 12, 2013, Pages 2115-2125

  Ching, James K ^a   Ju, Jeong Sun ^a   Pittman, Sara K ^a   Margeta, Marta ^b   Weihl, Conrad C ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autophagy; Colchicine; HMG CoA reductase inhibitor; Toxic myopathy; Vacuolar myopathy

Indexed keywords

CARDIOTOXIN; COLCHICINE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; RAPAMYCIN; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CELL VACUOLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; MOUSE; MUSCLE CELL; MUSCLE NECROSIS; MYOPATHY; NONHUMAN; PATHOGENESIS; TOXIC MYOPATHY;

ANIMALS; AUTOPHAGY; COLCHICINE; DISEASE PROGRESSION; HUMANS; LYSOSOMAL STORAGE DISEASES; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; MUSCULAR DISEASES; PHAGOSOMES; SIMVASTATIN; UP-REGULATION; VACUOLES;

EID: 84890814455     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/auto.26150     Document Type: Article

References (40)

1. Dalakas MC. Toxic and drug-induced myopathies. J Neurol Neurosurg Psychiatry 2009; 80:832-8; PMID:19608783; http://dx.doi.org/10.1136/jnnp.2008. 168294
2. Wilbur K, Makowsky M. Colchicine myotoxicity: case reports and literature review. Pharmacotherapy 2004; 24:1784-92; PMID:15585444; http://dx.doi.org/10. 1592/phco.24.17.1784.52334
3. Kuncl RW, Bilak MM, Craig SW, Adams R. Exocytotic " constipation" is a mechanism of tubulin/lysosomal interaction in colchicine myopathy. Exp Cell Res 2003; 285:196-207; PMID:12706115; http://dx.doi.org/10. 1016/S0014-4827(03)00034-X
4. Rubinsztein DC, Mariño G, Kroemer G. Autophagy and aging. Cell 2011; 146:682-95; PMID:21884931; http://dx.doi.org/10.1016/j.cell.2011.07.030
5. Ravikumar B, Acevedo-Arozena A, Imarisio S, Berger Z, Vacher C, O'Kane CJ, Brown SD, Rubinsztein DC. Dynein mutations impair autophagic clearance of aggregate-prone proteins. Nat Genet 2005; 37:771-6; PMID:15980862; http://dx.doi.org/10.1038/ng1591
6. Sandri M. Autophagy in skeletal muscle. FEBS Lett 2010; 584:1411-6; PMID:20132819; http://dx.doi.org/10.1016/j.febslet.2010.01.056
7. He C, Bassik MC, Moresi V, Sun K, Wei Y, Zou Z, An Z, Loh J, Fisher J, Sun Q, et al. Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. Nature 2012; 481:511-5; PMID:22258505; http://dx.doi.org/ 10.1038/nature10758
8. Ju JS, Varadhachary AS, Miller SE, Weihl CC. Quantitation of "autophagic flux" in mature skeletal muscle. Autophagy 2010; 6:929-35; PMID:20657169; http://dx.doi.org/10.4161/auto.6.7.12785
9. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013; 1:CD004816; PMID:23440795
10. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289:1681-90; PMID:12672737; http://dx.doi.org/10.1001/jama.289.13.1681
11. Baker SK, Goodwin S, Sur M, Tarnopolsky MA. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle Nerve 2004; 30:799-802; PMID:15389652; http://dx.doi.org/10.1002/mus.20135
12. Bouquié R, Deslandes G, Renaud C, Dailly E, Haloun A, Jolliet P. Colchicine-induced rhabdomyolysis in a heart/lung transplant patient with concurrent use of cyclosporin, pravastatin, and azithromycin. J Clin Rheumatol 2011; 17:28-30; PMID:21169852; http://dx.doi.org/10.1097/RHU.0b013e3182056042
13. Justiniano M, Dold S, Espinoza LR. Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine. J Clin Rheumatol 2007; 13:266-8; PMID:17921794; http://dx.doi.org/10.1097/RHU. 0b013e318156d977
14. Sarullo FM, Americo L, Di Franco A, Di Pasquale P. Rhabdomyolysis induced by co-administration of fluvastatin and colchicine. Monaldi Arch Chest Dis 2010; 74:147-9; PMID:21110512
15. Alayli G, Cengiz K, Cantürk F, Durmuş D, Akyol Y, Menekşe EB. Acute myopathy in a patient with concomitant use of pravastatin and colchicine. Ann Pharmacother 2005; 39:1358-61; PMID:15914514; http://dx.doi.org/10.1345/aph.1E593
16. Atasoyu EM, Evrenkaya TR, Solmazgul E. Possible colchicine rhabdomyolysis in a fluvastatin-treated patient. Ann Pharmacother 2005; 39:1368-9; PMID:15956236; http://dx.doi.org/10.1345/aph.1E653
17. Francis L, Bonilla E, Soforo E, Neupane H, Nakhla H, Fuller C, Perl A. Fatal toxic myopathy attributed to propofol, methylprednisolone, and cyclosporine after prior exposure to colchicine and simvastatin. Clin Rheumatol 2008; 27:129-31; PMID:17628739; http://dx.doi.org/10.1007/s10067-007-0696-9
18. Hsu WC, Chen WH, Chang MT, Chiu HC. Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin. Clin Neuropharmacol 2002; 25:266-8; PMID:12410059; http://dx.doi.org/10.1097/00002826-200209000-00008
19. Oh DH, Chan SQ, Wilson AM. Myopathy and possible intestinal dysfunction in a patient treated with colchicine and simvastatin. Med J Aust 2012; 197:332-3; PMID:22994827; http://dx.doi.org/10.5694/mja12.10333
20. Torgovnick J, Sethi N, Arsura E. Colchicine and HMG Co-A reductase inhibitors induced myopathy-a case report. Neurotoxicology 2006; 27:1126-7; PMID:17049607; http://dx.doi.org/10.1016/j.neuro.2006.09.003
21. Araki M, Maeda M, Motojima K. Hydrophobic statins induce autophagy and cell death in human rhabdomyosarcoma cells by depleting geranylgeranyl diphosphate. Eur J Pharmacol 2012; 674:95-103; PMID:22094060; http://dx.doi.org/10.1016/j.ejphar.2011.10.044
22. Araki M, Motojima K. Hydrophobic statins induce autophagy in cultured human rhabdomyosarcoma cells. Biochem Biophys Res Commun 2008; 367:462-7; PMID:18178158; http://dx.doi.org/10.1016/j.bbrc.2007.12.166
23. Lee HS, Daniels BH, Salas E, Bollen AW, Debnath J, Margeta M. Clinical utility of LC3 and p62 immunohistochemistry in diagnosis of drug-induced autophagic vacuolar myopathies: a case-control study. PLoS One 2012; 7:e36221; PMID:22558391; http://dx.doi.org/10.1371/journal.pone.0036221
24. Abdel-Hamid H, Oddis CV, Lacomis D. Severe hydroxychloroquine myopathy. Muscle Nerve 2008; 38:1206-10; PMID:18720511; http://dx.doi.org/10.1002/mus. 21091
25. Kumamoto T, Ueyama H, Watanabe S, Murakami T, Araki S. Effect of denervation on overdevelopment of chloroquine-induced autophagic vacuoles in skeletal muscles. Muscle Nerve 1993; 16:819-26; PMID:8332133; http://dx.doi.org/10.1002/mus.880160803
26. Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Del Piccolo P, Burden SJ, Di Lisi R, Sandri C, Zhao J, et al. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab 2007; 6:458-71; PMID:18054315; http://dx.doi.org/10.1016/j.cmet.2007.11.001
27. Zhao J, Brault JJ, Schild A, Cao P, Sandri M, Schiaffino S, Lecker SH, Goldberg AL. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab 2007; 6:472-83; PMID:18054316; http://dx.doi.org/10.1016/j.cmet.2007.11. 004
28. Malicdan MC, Noguchi S, Nonaka I, Saftig P, Nishino I. Lysosomal myopathies: an excessive build-up in autophagosomes is too much to handle. Neuromuscul Disord 2008; 18:521-9; PMID:18502640; http://dx.doi.org/10.1016/j. nmd.2008.04.010
29. Ching JK, Elizabeth SV, Ju JS, Lusk C, Pittman SK, Weihl CC. mTOR dysfunction contributes to vacuolar pathology and weakness in valosin-containing protein associated inclusion body myopathy. Hum Mol Genet 2013; 22:1167-79; PMID:23250913; http://dx.doi.org/10.1093/hmg/dds524
30. Ju JS, Fuentealba RA, Miller SE, Jackson E, Piwnica-Worms D, Baloh RH, Weihl CC. Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. J Cell Biol 2009; 187:875-88; PMID:20008565; http://dx.doi.org/10.1083/jcb.200908115
31. Nogalska A, D'Agostino C, Terracciano C, Engel WK, Askanas V. Impaired autophagy in sporadic inclusion-body myositis and in endoplasmic reticulum stress-provoked cultured human muscle fibers. Am J Pathol 2010; 177:1377-87; PMID:20616343; http://dx.doi.org/10.2353/ajpath.2010.100050
32. Ramachandran N, Munteanu I, Wang P, Ruggieri A, Rilstone JJ, Israelian N, Naranian T, Paroutis P, Guo R, Ren ZP, et al. VMA21 deficiency prevents vacuolar ATPase assembly and causes autophagic vacuolar myopathy. Acta Neuropathol 2013; 125:439-57; PMID:23315026; http://dx.doi.org/10.1007/s00401- 012-1073-6
33. Parikh A, Childress C, Deitrick K, Lin Q, Rukstalis D, Yang W. Statin-induced autophagy by inhibition of geranylgeranyl biosynthesis in prostate cancer PC3 cells. Prostate 2010; 70:971-81; PMID:20135644; http://dx.doi.org/10.1002/pros.21131
34. Wasko BM, Dudakovic A, Hohl RJ. Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate. J Pharmacol Exp Ther 2011; 337:540-6; PMID:21335425; http://dx.doi.org/10.1124/jpet.110.175521
35. Pan J, Chen B, Su CH, Zhao R, Xu ZX, Sun L, Lee MH, Yeung SC. Autophagy induced by farnesyltransferase inhibitors in cancer cells. Cancer Biol Ther 2008; 7:1679-84; PMID:18769123; http://dx.doi.org/10.4161/cbt.7.10.6661
36. Ghavami S, Mutawe MM, Schaafsma D, Yeganeh B, Unruh H, Klonisch T, Halayko AJ. Geranylgeranyl transferase 1 modulates autophagy and apoptosis in human airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2012; 302:L420-8; PMID:22160308; http://dx.doi.org/10.1152/ajplung.00312.2011
37. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370:1781-90; PMID:17559928; http://dx.doi.org/10.1016/S0140-6736(07)60716-8
38. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R; SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med 2008; 359:789-99; PMID:18650507; http://dx.doi.org/10.1056/NEJMoa0801936
39. Weihl CC, Miller SE, Hanson PI, Pestronk A. Transgenic expression of inclusion body myopathy associated mutant p97/VCP causes weakness and ubiquitinated protein inclusions in mice. Hum Mol Genet 2007; 16:919-28; PMID:17329348; http://dx.doi.org/10.1093/hmg/ddm037
40. Karnovsky MJ. A formaldehyde-glutaraldehyde fixative of high osmolarity for use in electron microscopy. J Cell Biol 1965; 27:137A-8A